A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

20061,438 citationsJournal Articlegreen Open Access

Authors

Ting‐Tsung Chang · National Cheng Kung University

Robert G. Gish · California Pacific Medical Center

Robert de Man · Rotterdam University of Applied Sciences

Adrián Gadano · Hospital Italiano de Buenos Aires

Jose D. Sollano · University of Santo Tomas

You‐Chen Chao · Tri-Service General Hospital

Anna S. Lok

Abstract

Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine. The safety profile of the two agents is similar, and there is no evidence of viral resistance to entecavir. (ClinicalTrials.gov number, NCT00035633.).

Topics & Keywords

Hepatitis B Virus Studies Hepatitis C virus research Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 10, pp. 1001-1010

DOI: 10.1056/nejmoa051285

Field-Weighted Citation Impact: 92.16